ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
3
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
3
U.S. (TOLL FREE)
+1 (315) 215-3225
Global CINV Existing and Pipeline Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-17V10044
Home | Market Reports | Health| Health Conditions| Cancer
Global CINV Existing and Pipeline Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global CINV Existing and Pipeline Drugs Market Research Report 2025

Code: QYRE-Auto-17V10044
Report
August 2025
Pages:72
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GlaxoSmithKline PLC
Helsinn
Heron Therapeutics
Merck
Tesaro

CINV Existing and Pipeline Drugs Market Size

The global market for CINV Existing and Pipeline Drugs was valued at US$ 1665 million in the year 2024 and is projected to reach a revised size of US$ 2069 million by 2031, growing at a CAGR of 3.2% during the forecast period.

CINV Existing and Pipeline Drugs Market

CINV Existing and Pipeline Drugs Market

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for CINV Existing and Pipeline Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CINV Existing and Pipeline Drugs.
The CINV Existing and Pipeline Drugs market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CINV Existing and Pipeline Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CINV Existing and Pipeline Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of CINV Existing and Pipeline Drugs Market Report

Report Metric Details
Report Name CINV Existing and Pipeline Drugs Market
Accounted market size in year US$ 1665 million
Forecasted market size in 2031 US$ 2069 million
CAGR 3.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Aloxi
  • Zofran Generic
  • Kytril Generic
  • Emend
  • Akynzeo
  • SUSTOL
  • Rolapitant
Segment by Application
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers Therapeutics
  • Hospital Pharmacies
  • Drugstores
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of CINV Existing and Pipeline Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is CINV Existing and Pipeline Drugs Market growing?

Ans: The CINV Existing and Pipeline Drugs Market witnessing a CAGR of 3.2% during the forecast period 2025-2031.

What is the CINV Existing and Pipeline Drugs Market size in 2031?

Ans: The CINV Existing and Pipeline Drugs Market size in 2031 will be US$ 2069 million.

Who are the main players in the CINV Existing and Pipeline Drugs Market report?

Ans: The main players in the CINV Existing and Pipeline Drugs Market are GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro

What are the Application segmentation covered in the CINV Existing and Pipeline Drugs Market report?

Ans: The Applications covered in the CINV Existing and Pipeline Drugs Market report are Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores

What are the Type segmentation covered in the CINV Existing and Pipeline Drugs Market report?

Ans: The Types covered in the CINV Existing and Pipeline Drugs Market report are Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL, Rolapitant

1 CINV Existing and Pipeline Drugs Market Overview
1.1 Product Definition
1.2 CINV Existing and Pipeline Drugs by Type
1.2.1 Global CINV Existing and Pipeline Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Aloxi
1.2.3 Zofran Generic
1.2.4 Kytril Generic
1.2.5 Emend
1.2.6 Akynzeo
1.2.7 SUSTOL
1.2.8 Rolapitant
1.3 CINV Existing and Pipeline Drugs by Application
1.3.1 Global CINV Existing and Pipeline Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Diagnostic Centers Therapeutics
1.3.5 Hospital Pharmacies
1.3.6 Drugstores
1.4 Global CINV Existing and Pipeline Drugs Market Size Estimates and Forecasts
1.4.1 Global CINV Existing and Pipeline Drugs Revenue 2020-2031
1.4.2 Global CINV Existing and Pipeline Drugs Sales 2020-2031
1.4.3 Global CINV Existing and Pipeline Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 CINV Existing and Pipeline Drugs Market Competition by Manufacturers
2.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global CINV Existing and Pipeline Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of CINV Existing and Pipeline Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Type & Application
2.7 Global Key Manufacturers of CINV Existing and Pipeline Drugs, Date of Enter into This Industry
2.8 Global CINV Existing and Pipeline Drugs Market Competitive Situation and Trends
2.8.1 Global CINV Existing and Pipeline Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest CINV Existing and Pipeline Drugs Players Market Share by Revenue
2.8.3 Global CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global CINV Existing and Pipeline Drugs Market Scenario by Region
3.1 Global CINV Existing and Pipeline Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global CINV Existing and Pipeline Drugs Sales by Region: 2020-2031
3.2.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2020-2025
3.2.2 Global CINV Existing and Pipeline Drugs Sales by Region: 2026-2031
3.3 Global CINV Existing and Pipeline Drugs Revenue by Region: 2020-2031
3.3.1 Global CINV Existing and Pipeline Drugs Revenue by Region: 2020-2025
3.3.2 Global CINV Existing and Pipeline Drugs Revenue by Region: 2026-2031
3.4 North America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.4.1 North America CINV Existing and Pipeline Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America CINV Existing and Pipeline Drugs Sales by Country (2020-2031)
3.4.3 North America CINV Existing and Pipeline Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.5.1 Europe CINV Existing and Pipeline Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2031)
3.5.3 Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CINV Existing and Pipeline Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific CINV Existing and Pipeline Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific CINV Existing and Pipeline Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.7.1 Latin America CINV Existing and Pipeline Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America CINV Existing and Pipeline Drugs Sales by Country (2020-2031)
3.7.3 Latin America CINV Existing and Pipeline Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CINV Existing and Pipeline Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global CINV Existing and Pipeline Drugs Sales by Type (2020-2031)
4.1.1 Global CINV Existing and Pipeline Drugs Sales by Type (2020-2025)
4.1.2 Global CINV Existing and Pipeline Drugs Sales by Type (2026-2031)
4.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2031)
4.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2020-2031)
4.2.1 Global CINV Existing and Pipeline Drugs Revenue by Type (2020-2025)
4.2.2 Global CINV Existing and Pipeline Drugs Revenue by Type (2026-2031)
4.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2020-2031)
4.3 Global CINV Existing and Pipeline Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global CINV Existing and Pipeline Drugs Sales by Application (2020-2031)
5.1.1 Global CINV Existing and Pipeline Drugs Sales by Application (2020-2025)
5.1.2 Global CINV Existing and Pipeline Drugs Sales by Application (2026-2031)
5.1.3 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2031)
5.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2020-2031)
5.2.1 Global CINV Existing and Pipeline Drugs Revenue by Application (2020-2025)
5.2.2 Global CINV Existing and Pipeline Drugs Revenue by Application (2026-2031)
5.2.3 Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2020-2031)
5.3 Global CINV Existing and Pipeline Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Company Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Helsinn
6.2.1 Helsinn Company Information
6.2.2 Helsinn Description and Business Overview
6.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
6.2.5 Helsinn Recent Developments/Updates
6.3 Heron Therapeutics
6.3.1 Heron Therapeutics Company Information
6.3.2 Heron Therapeutics Description and Business Overview
6.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
6.3.5 Heron Therapeutics Recent Developments/Updates
6.4 Merck
6.4.1 Merck Company Information
6.4.2 Merck Description and Business Overview
6.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
6.4.5 Merck Recent Developments/Updates
6.5 Tesaro
6.5.1 Tesaro Company Information
6.5.2 Tesaro Description and Business Overview
6.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
6.5.5 Tesaro Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CINV Existing and Pipeline Drugs Industry Chain Analysis
7.2 CINV Existing and Pipeline Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CINV Existing and Pipeline Drugs Production Mode & Process Analysis
7.4 CINV Existing and Pipeline Drugs Sales and Marketing
7.4.1 CINV Existing and Pipeline Drugs Sales Channels
7.4.2 CINV Existing and Pipeline Drugs Distributors
7.5 CINV Existing and Pipeline Drugs Customer Analysis
8 CINV Existing and Pipeline Drugs Market Dynamics
8.1 CINV Existing and Pipeline Drugs Industry Trends
8.2 CINV Existing and Pipeline Drugs Market Drivers
8.3 CINV Existing and Pipeline Drugs Market Challenges
8.4 CINV Existing and Pipeline Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GlaxoSmithKline PLC
Helsinn
Heron Therapeutics
Merck
Tesaro
List of Tables
 Table 1. Global CINV Existing and Pipeline Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global CINV Existing and Pipeline Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global CINV Existing and Pipeline Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global CINV Existing and Pipeline Drugs Sales (Kg) of Key Manufacturers (2020-2025)
 Table 5. Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global CINV Existing and Pipeline Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global CINV Existing and Pipeline Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market CINV Existing and Pipeline Drugs Average Price (USD/Kg) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of CINV Existing and Pipeline Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of CINV Existing and Pipeline Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of CINV Existing and Pipeline Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of CINV Existing and Pipeline Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CINV Existing and Pipeline Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global CINV Existing and Pipeline Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global CINV Existing and Pipeline Drugs Sales by Region (2020-2025) & (Kg)
 Table 18. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global CINV Existing and Pipeline Drugs Sales by Region (2026-2031) & (Kg)
 Table 20. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global CINV Existing and Pipeline Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global CINV Existing and Pipeline Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global CINV Existing and Pipeline Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America CINV Existing and Pipeline Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
 Table 27. North America CINV Existing and Pipeline Drugs Sales by Country (2026-2031) & (Kg)
 Table 28. North America CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America CINV Existing and Pipeline Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe CINV Existing and Pipeline Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
 Table 32. Europe CINV Existing and Pipeline Drugs Sales by Country (2026-2031) & (Kg)
 Table 33. Europe CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe CINV Existing and Pipeline Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific CINV Existing and Pipeline Drugs Sales by Region (2020-2025) & (Kg)
 Table 37. Asia Pacific CINV Existing and Pipeline Drugs Sales by Region (2026-2031) & (Kg)
 Table 38. Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific CINV Existing and Pipeline Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America CINV Existing and Pipeline Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
 Table 42. Latin America CINV Existing and Pipeline Drugs Sales by Country (2026-2031) & (Kg)
 Table 43. Latin America CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America CINV Existing and Pipeline Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2020-2025) & (Kg)
 Table 47. Middle East and Africa CINV Existing and Pipeline Drugs Sales by Country (2026-2031) & (Kg)
 Table 48. Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global CINV Existing and Pipeline Drugs Sales (Kg) by Type (2020-2025)
 Table 51. Global CINV Existing and Pipeline Drugs Sales (Kg) by Type (2026-2031)
 Table 52. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global CINV Existing and Pipeline Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global CINV Existing and Pipeline Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global CINV Existing and Pipeline Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global CINV Existing and Pipeline Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global CINV Existing and Pipeline Drugs Price (USD/Kg) by Type (2020-2025)
 Table 59. Global CINV Existing and Pipeline Drugs Price (USD/Kg) by Type (2026-2031)
 Table 60. Global CINV Existing and Pipeline Drugs Sales (Kg) by Application (2020-2025)
 Table 61. Global CINV Existing and Pipeline Drugs Sales (Kg) by Application (2026-2031)
 Table 62. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global CINV Existing and Pipeline Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global CINV Existing and Pipeline Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global CINV Existing and Pipeline Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global CINV Existing and Pipeline Drugs Price (USD/Kg) by Application (2020-2025)
 Table 69. Global CINV Existing and Pipeline Drugs Price (USD/Kg) by Application (2026-2031)
 Table 70. GlaxoSmithKline Company Information
 Table 71. GlaxoSmithKline Description and Business Overview
 Table 72. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 73. GlaxoSmithKline CINV Existing and Pipeline Drugs Product
 Table 74. GlaxoSmithKline Recent Developments/Updates
 Table 75. Helsinn Company Information
 Table 76. Helsinn Description and Business Overview
 Table 77. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 78. Helsinn CINV Existing and Pipeline Drugs Product
 Table 79. Helsinn Recent Developments/Updates
 Table 80. Heron Therapeutics Company Information
 Table 81. Heron Therapeutics Description and Business Overview
 Table 82. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 83. Heron Therapeutics CINV Existing and Pipeline Drugs Product
 Table 84. Heron Therapeutics Recent Developments/Updates
 Table 85. Merck Company Information
 Table 86. Merck Description and Business Overview
 Table 87. Merck CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 88. Merck CINV Existing and Pipeline Drugs Product
 Table 89. Merck Recent Developments/Updates
 Table 90. Tesaro Company Information
 Table 91. Tesaro Description and Business Overview
 Table 92. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
 Table 93. Tesaro CINV Existing and Pipeline Drugs Product
 Table 94. Tesaro Recent Developments/Updates
 Table 95. Key Raw Materials Lists
 Table 96. Raw Materials Key Suppliers Lists
 Table 97. CINV Existing and Pipeline Drugs Distributors List
 Table 98. CINV Existing and Pipeline Drugs Customers List
 Table 99. CINV Existing and Pipeline Drugs Market Trends
 Table 100. CINV Existing and Pipeline Drugs Market Drivers
 Table 101. CINV Existing and Pipeline Drugs Market Challenges
 Table 102. CINV Existing and Pipeline Drugs Market Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Product Picture of CINV Existing and Pipeline Drugs
 Figure 2. Global CINV Existing and Pipeline Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global CINV Existing and Pipeline Drugs Market Share by Type: 2024 & 2031
 Figure 4. Aloxi Product Picture
 Figure 5. Zofran Generic Product Picture
 Figure 6. Kytril Generic Product Picture
 Figure 7. Emend Product Picture
 Figure 8. Akynzeo Product Picture
 Figure 9. SUSTOL Product Picture
 Figure 10. Rolapitant Product Picture
 Figure 11. Global CINV Existing and Pipeline Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 12. Global CINV Existing and Pipeline Drugs Market Share by Application: 2024 & 2031
 Figure 13. Hospitals
 Figure 14. Specialty Clinics
 Figure 15. Diagnostic Centers Therapeutics
 Figure 16. Hospital Pharmacies
 Figure 17. Drugstores
 Figure 18. Global CINV Existing and Pipeline Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 19. Global CINV Existing and Pipeline Drugs Market Size (2020-2031) & (US$ Million)
 Figure 20. Global CINV Existing and Pipeline Drugs Sales (2020-2031) & (Kg)
 Figure 21. Global CINV Existing and Pipeline Drugs Average Price (USD/Kg) & (2020-2031)
 Figure 22. CINV Existing and Pipeline Drugs Report Years Considered
 Figure 23. CINV Existing and Pipeline Drugs Sales Share by Manufacturers in 2024
 Figure 24. Global CINV Existing and Pipeline Drugs Revenue Share by Manufacturers in 2024
 Figure 25. Global 5 and 10 Largest CINV Existing and Pipeline Drugs Players: Market Share by Revenue in CINV Existing and Pipeline Drugs in 2024
 Figure 26. CINV Existing and Pipeline Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 27. Global CINV Existing and Pipeline Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 28. North America CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2031)
 Figure 29. North America CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2031)
 Figure 30. U.S. CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Canada CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Europe CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2031)
 Figure 33. Europe CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2031)
 Figure 34. Germany CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. France CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. U.K. CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Italy CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Russia CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Asia Pacific CINV Existing and Pipeline Drugs Sales Market Share by Region (2020-2031)
 Figure 40. Asia Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Region (2020-2031)
 Figure 41. China CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Japan CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. South Korea CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. India CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Australia CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Taiwan CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Indonesia CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Thailand CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Malaysia CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Philippines CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Latin America CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2031)
 Figure 52. Latin America CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2031)
 Figure 53. Mexico CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Brazil CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Argentina CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Country (2020-2031)
 Figure 57. Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Country (2020-2031)
 Figure 58. Turkey CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Saudi Arabia CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 60. U.A.E CINV Existing and Pipeline Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 61. Global Sales Market Share of CINV Existing and Pipeline Drugs by Type (2020-2031)
 Figure 62. Global Revenue Market Share of CINV Existing and Pipeline Drugs by Type (2020-2031)
 Figure 63. Global CINV Existing and Pipeline Drugs Price (USD/Kg) by Type (2020-2031)
 Figure 64. Global Sales Market Share of CINV Existing and Pipeline Drugs by Application (2020-2031)
 Figure 65. Global Revenue Market Share of CINV Existing and Pipeline Drugs by Application (2020-2031)
 Figure 66. Global CINV Existing and Pipeline Drugs Price (USD/Kg) by Application (2020-2031)
 Figure 67. CINV Existing and Pipeline Drugs Value Chain
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Radioactive Iodine Ablation Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9U20281
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32T20006
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-0Q20500
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-18V16958
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions